Nektar Therapeutics hits downward sloped trend line and gets bearish signal
Nektar Therapeutics (Nasdaq: NKTR) is a biopharmaceutical company that drugs for cancer, autoimmune diseases, and chronic pain. The company’s fundamental indicators are all over the place, but the stock has been trending lower since September.
If we connect the closing high from September with intraday high from February, it creates a trend line that the stock just hit in the last few days. We see the trend line on the daily chart, but what we don’t see on the daily chart is that the high from September was in close proximity to a gap in the chart from 2018. That gap was in the $70 area.
We also see that the daily stochastic readings and the 10-day RSI had reached overbought levels in the last few days before they turned lower on Friday and Monday.
The Tickeron AI Trend Prediction tool generated a bearish signal on the stock on May 10. The signal only showed a confidence level of 59%, but the past signals on Nektar have been successful 90% of the time. This prediction calls for a 2.5% decline in the next week.
I mentioned earlier that Nektar’s fundamentals are over the place. Earnings have been flat over the last three years and fell by 13% in the most recent quarterly report. Sales have increased by a rate of 128% per year over the last three years, but fell by 26% in the most recent quarter. The ROE is at 75.5% and the profit margin is at 57.2%. Both of those figures are well above average.
NKTR in downward trend: price dove below 50-day moving average on November 20, 2025
NKTR moved below its 50-day moving average on November 20, 2025 date and that indicates a change from an upward trend to a downward trend. In of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where NKTR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on November 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTR as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for NKTR crossed bearishly below the 50-day moving average on November 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTR advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .
NKTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 151 cases where NKTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NKTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.970) is normal, around the industry mean (27.115). P/E Ratio (0.000) is within average values for comparable stocks, (51.613). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.036). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (13.245) is also within normal values, averaging (317.729).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of inhalation drug delivery systems
Industry Biotechnology
Advertisement